144 related articles for article (PubMed ID: 29148865)
1. Metronomic therapy has low toxicity and is as effective as current standard treatment for recurrent high-risk neuroblastoma.
Berthold F; Hömberg M; Proleskovskaya I; Mazanek P; Belogurova M; Ernst A; Sterba J
Pediatr Hematol Oncol; 2017 Aug; 34(5):308-319. PubMed ID: 29148865
[TBL] [Abstract][Full Text] [Related]
2. All-oral metronomic DEVEC schedule in elderly patients with peripheral T cell lymphoma.
Cox MC; Banchi M; Pelliccia S; Di Napoli A; Marcheselli L; Patti C; Anticoli Borza P; Battistini R; Di Gregorio F; Orlandi P; Bocci G
Cancer Chemother Pharmacol; 2020 Dec; 86(6):841-846. PubMed ID: 33070248
[TBL] [Abstract][Full Text] [Related]
3. Pilot study of a pediatric metronomic 4-drug regimen.
André N; Abed S; Orbach D; Alla CA; Padovani L; Pasquier E; Gentet JC; Verschuur A
Oncotarget; 2011 Dec; 2(12):960-5. PubMed ID: 22156656
[TBL] [Abstract][Full Text] [Related]
4. Oral metronomic chemotherapy for recurrent & refractory epithelial ovarian cancer: A retrospective analysis.
Sharma A; Malik PS; Khurana S; Kumar S; Bhatla N; Ray MD; Kumar L
Indian J Med Res; 2019 Dec; 150(6):575-583. PubMed ID: 32048620
[TBL] [Abstract][Full Text] [Related]
5. Combined continuous infusion etoposide with high-dose cyclophosphamide for refractory neuroblastoma: a phase II study from the Société Française d'Oncologie Pédiatrique.
Méresse V; Vassal G; Michon J; De Cervens C; Courbon B; Rubie H; Perel Y; Landman J; Chastagnier P; De Valck C
J Clin Oncol; 1993 Apr; 11(4):630-7. PubMed ID: 8478658
[TBL] [Abstract][Full Text] [Related]
6. Topotecan, cyclophosphamide, and etoposide (TCE) in the treatment of high-risk neuroblastoma. Results of a phase-II trial.
Simon T; Längler A; Harnischmacher U; Frühwald MC; Jorch N; Claviez A; Berthold F; Hero B
J Cancer Res Clin Oncol; 2007 Sep; 133(9):653-61. PubMed ID: 17479288
[TBL] [Abstract][Full Text] [Related]
7. A pilot study of low-dose anti-angiogenic chemotherapy in combination with standard multiagent chemotherapy for patients with newly diagnosed metastatic Ewing sarcoma family of tumors: A Children's Oncology Group (COG) Phase II study NCT00061893.
Felgenhauer JL; Nieder ML; Krailo MD; Bernstein ML; Henry DW; Malkin D; Baruchel S; Chuba PJ; Sailer SL; Brown K; Ranganathan S; Marina N
Pediatr Blood Cancer; 2013 Mar; 60(3):409-14. PubMed ID: 23065953
[TBL] [Abstract][Full Text] [Related]
8. Retrospective Analysis of Outcomes of Patients with Relapsed, Refractory and Metastatic Sarcomas who have received Metronomic Chemotherapy.
Devadas SK; Banavali S
Gulf J Oncolog; 2019 May; 1(30):22-28. PubMed ID: 31242978
[TBL] [Abstract][Full Text] [Related]
9. A phase I study of sirolimus in combination with metronomic therapy (CHOAnome) in children with recurrent or refractory solid and brain tumors.
Qayed M; Cash T; Tighiouart M; MacDonald TJ; Goldsmith KC; Tanos R; Kean L; Watkins B; Suessmuth Y; Wetmore C; Katzenstein HM
Pediatr Blood Cancer; 2020 Apr; 67(4):e28134. PubMed ID: 31876107
[TBL] [Abstract][Full Text] [Related]
10. Metastatic breast cancer patients treated with low-dose metronomic chemotherapy with cyclophosphamide and celecoxib: clinical outcomes and biomarkers of response.
Perroud HA; Alasino CM; Rico MJ; Mainetti LE; Queralt F; Pezzotto SM; Rozados VR; Scharovsky OG
Cancer Chemother Pharmacol; 2016 Feb; 77(2):365-74. PubMed ID: 26721701
[TBL] [Abstract][Full Text] [Related]
11. Percentage tumor necrosis following chemotherapy in neuroblastoma correlates with MYCN status but not survival.
Bomken S; Davies B; Chong L; Cole M; Wood KM; McDermott M; Tweddle DA
Pediatr Hematol Oncol; 2011 Mar; 28(2):106-14. PubMed ID: 21214410
[TBL] [Abstract][Full Text] [Related]
12. Effective Management of Advanced Angiosarcoma by the Synergistic Combination of Propranolol and Vinblastine-based Metronomic Chemotherapy: A Bench to Bedside Study.
Pasquier E; André N; Street J; Chougule A; Rekhi B; Ghosh J; Philip DSJ; Meurer M; MacKenzie KL; Kavallaris M; Banavali SD
EBioMedicine; 2016 Apr; 6():87-95. PubMed ID: 27211551
[TBL] [Abstract][Full Text] [Related]
13. N7: a novel multi-modality therapy of high risk neuroblastoma (NB) in children diagnosed over 1 year of age.
Cheung NK; Kushner BH; LaQuaglia M; Kramer K; Gollamudi S; Heller G; Gerald W; Yeh S; Finn R; Larson SM; Wuest D; Byrnes M; Dantis E; Mora J; Cheung IY; Rosenfield N; Abramson S; O'Reilly RJ
Med Pediatr Oncol; 2001 Jan; 36(1):227-30. PubMed ID: 11464891
[TBL] [Abstract][Full Text] [Related]
14. Evolution and contemporary role of metronomic chemotherapy in the treatment of neuroblastoma.
Chou SW; Chang HH
Cancer Lett; 2024 Apr; 588():216617. PubMed ID: 38311055
[TBL] [Abstract][Full Text] [Related]
15. Metronomic Chemotherapy vs Best Supportive Care in Progressive Pediatric Solid Malignant Tumors: A Randomized Clinical Trial.
Pramanik R; Agarwala S; Gupta YK; Thulkar S; Vishnubhatla S; Batra A; Dhawan D; Bakhshi S
JAMA Oncol; 2017 Sep; 3(9):1222-1227. PubMed ID: 28384657
[TBL] [Abstract][Full Text] [Related]
16. A pilot pharmacokinetic and antiangiogenic biomarker study of celecoxib and low-dose metronomic vinblastine or cyclophosphamide in pediatric recurrent solid tumors.
Stempak D; Gammon J; Halton J; Moghrabi A; Koren G; Baruchel S
J Pediatr Hematol Oncol; 2006 Nov; 28(11):720-8. PubMed ID: 17114958
[TBL] [Abstract][Full Text] [Related]
17. Phase II study of metronomic chemotherapy for recurrent malignant gliomas in adults.
Kesari S; Schiff D; Doherty L; Gigas DC; Batchelor TT; Muzikansky A; O'Neill A; Drappatz J; Chen-Plotkin AS; Ramakrishna N; Weiss SE; Levy B; Bradshaw J; Kracher J; Laforme A; Black PM; Folkman J; Kieran M; Wen PY
Neuro Oncol; 2007 Jul; 9(3):354-63. PubMed ID: 17452651
[TBL] [Abstract][Full Text] [Related]
18. Sustained Survival Benefit in Recurrent Medulloblastoma by a Metronomic Antiangiogenic Regimen: A Nonrandomized Controlled Trial.
Peyrl A; Chocholous M; Sabel M; Lassaletta A; Sterba J; Leblond P; Nysom K; Torsvik I; Chi SN; Perwein T; Jones N; Holm S; Nyman P; Mörse H; Öberg A; Weiler-Wichtl L; Leiss U; Haberler C; Schmook MT; Mayr L; Dieckmann K; Kool M; Gojo J; Azizi AA; André N; Kieran M; Slavc I
JAMA Oncol; 2023 Dec; 9(12):1688-1695. PubMed ID: 37883081
[TBL] [Abstract][Full Text] [Related]
19. A phase II trial of a multi-agent oral antiangiogenic (metronomic) regimen in children with recurrent or progressive cancer.
Robison NJ; Campigotto F; Chi SN; Manley PE; Turner CD; Zimmerman MA; Chordas CA; Werger AM; Allen JC; Goldman S; Rubin JB; Isakoff MS; Pan WJ; Khatib ZA; Comito MA; Bendel AE; Pietrantonio JB; Kondrat L; Hubbs SM; Neuberg DS; Kieran MW
Pediatr Blood Cancer; 2014 Apr; 61(4):636-42. PubMed ID: 24123865
[TBL] [Abstract][Full Text] [Related]
20. Topotecan and etoposide in the treatment of relapsed high-risk neuroblastoma: results of a phase 2 trial.
Simon T; Längler A; Berthold F; Klingebiel T; Hero B
J Pediatr Hematol Oncol; 2007 Feb; 29(2):101-6. PubMed ID: 17279006
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
